GeoVax Labs, Inc. announced it has implemented a 1-for-500 reverse stock split of its common stock with a market effective date of May 2, 2019.
- 1:500 Reverse Split Effective May 2, 2019;
- Ticker Symbol Changed to GOVXD for 20 Days
ATLANTA, GA, May 3, 2019 – GeoVax Labs, Inc. (OTCQB: GOVX) today announced it has implemented a 1-for-500 reverse stock split of its common stock with a market effective date of May 2, 2019. For the 20-business day period beginning May 2, 2019, GeoVax’s ticker symbol will be “GOVXD” to reflect the post-split price. Following that period, the ticker symbol will revert to “GOVX.”
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.
GeoVax’s current development programs are focused on preventive vaccines against HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against chronic Hepatitis B infections and cancers. The Company has designed the leading preventative HIV vaccine candidate to fight against the subtype of HIV prevalent in the larger commercial markets of the Americas, Western Europe, Japan, and Australia; this program is currently undergoing human clinical trials managed by the HIV Vaccine Trials Network (HVTN) with the support of the National Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of collaborative efforts to develop an immunotherapy as a functional cure for HIV.
GeoVax’s corporate strategy is to improve the health of patients worldwide by advancing its patented vaccine platform, using its unique capabilities to design and develop an array of products addressing unmet medical needs in the areas of infectious diseases and oncology. The Company intends to advance its products toward human clinical testing, and to seek partnership or licensing arrangements for commercialization. GeoVax’s strategy includes leveraging third party resources through government, academic and corporate research collaborations, and partnerships for preclinical and clinical testing.
For more information, visit www.geovax.com.
Contact:
GeoVax Labs, Inc.
678-384-7220
